AIP
CGON icon

Arrowpoint Investment Partners’s CG Oncology CGON Stock Holding History

Arrowpoint Investment Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,370
Closed -$228K – 136
2026
Q1 		$228K Buy
+3,370
New +$191K 0.2% 67

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowpoint Investment Partners's CGON Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 3,370 shares — an estimated $228K sold.

Arrowpoint Investment Partners first reported a position in CGON in Q1 2026 and held it in 1 quarter. The position peaked at $228K in Q1 2026. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 3,370 CG Oncology shares in Q2 2026, an estimated $228K.
  • Arrowpoint Investment Partners first reported a position in CG Oncology in Q1 2026 and held it in 1 quarter.
  • Arrowpoint Investment Partners's CG Oncology position peaked at $228K in Q1 2026.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.